Theodor Sauer, MD
Ophthalmology · Boston, MANPI 1679916639
Payments from drug & device makers
Across 51 payments — averaging $251.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$10K
- AbbVie$1K
- Sight Sciences, Inc.$646
- Rxsight Inc$302
- Nova Eye, Inc.$201
- Oyster Point Pharma, Inc.$125
- plus $281 from 8 others
Across 6 payments — averaging $117.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$703
What the payments were for
- Consulting fees$10,00078%
- Food & beverage$2,79122%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 5 | $10,190 |
| AbbVie(2 entities) | 18 | $1,091 |
| Sight Sciences, Inc. | 11 | $646 |
| Rxsight Inc | 3 | $302 |
| Nova Eye, Inc. | 1 | $201 |
| Oyster Point Pharma, Inc. | 1 | $125 |
| Bausch & Lomb Americas Inc. | 3 | $74 |
| Alcon | 2 | $59 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Dompe US, Inc. | 1 | $34 |
| Thea Pharma Inc. | 1 | $22 |
| NEW World Medical,inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$10,000
- OMNI(R) SURGICAL SYSTEM (US)$437
- RXSIGHT CONTACT LENS$278
- RXSIGHT INJECTOR CARTRIDGE$278
- RXSIGHT INJECTOR HANDPIECE$278
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$278
- LIGHT ADJUSTABLE LENS (LAL)$278
- XEN GLAUCOMA TREATMENT SYSTEM$236
- SION SURGICAL INSTRUMENT$147
- XEN$138
- TYRVAYA$125
- DURYSTA$125
- OMNI$112
How this compares
$12,836 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 88 | $56,825 |
| VyzultaLatanoprostene Bunod | 61 | $39,342 |
| RestasisCyclosporine | 30 | $37,896 |
| LumiganBimatoprost | 63 | $30,741 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $26,219 |
| Prednisolone Acetate | 605 | $22,416 |
| Latanoprost | 1,189 | $19,716 |
| Alphagan PBrimonidine Tartrate | 34 | $17,755 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 40 | $14,419 |
| Timolol MaleateTimolol Maleate/Pf | 31 | $12,588 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $12,263 |
| TafluprostTafluprost/Pf | 57 | $11,423 |
| Brimonidine Tartrate | 359 | $9,568 |
| Restasis MultidoseCyclosporine | 15 | $9,460 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 388 | $9,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan, Restasis Multidose | $1,091 | $108,115166 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $74 | $39,34261 claims |
| AlconSimbrinza | $59 | $14,41940 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $40 | $2,76819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Boston
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Jack GreinerBoston$523K
- Reza DanaBoston$510K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- David FriedmanBoston$259K
- Dean EliottBoston$250K
- Michael RaizmanBoston$237K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.